Publications by authors named "Peter Traxler"

9Publications

Pooled CRISPR screening with single-cell transcriptome readout.

Authors:
Paul Datlinger André F Rendeiro Christian Schmidl Thomas Krausgruber Peter Traxler Johanna Klughammer Linda C Schuster Amelie Kuchler Donat Alpar Christoph Bock

Nat Methods 2017 03 18;14(3):297-301. Epub 2017 Jan 18.

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

View Article and Find Full Text PDF
March 2017

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.

Authors:
Maximilien Murone Anne Vaslin Chessex Antoine Attinger Raghuveer Ramachandra Shankar J Shetty Girish Daginakatte Saumitra Sengupta Sivapriya Marappan Samiulla Dhodheri Stefania Rigotti Yogeshwar Bachhav Silvano Brienza Peter Traxler Marc Lang Michel Aguet Vincent Zoete Olivier Michielin Courtney Nicholas Faye M Johnson Murali Ramachandra Andres McAllister

Mol Cancer Ther 2016 10 20;15(10):2334-2343. Epub 2016 Jul 20.

Debiopharm International S.A., Lausanne, Switzerland.

View Article and Find Full Text PDF
October 2016

Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Authors:
Ranjit K Goudar Qing Shi Mark D Hjelmeland Stephen T Keir Roger E McLendon Carol J Wikstrand Elizabeth D Reese Charles A Conrad Peter Traxler Heidi A Lane David A Reardon Webster K Cavenee Xiao-Fan Wang Darell D Bigner Henry S Friedman Jeremy N Rich

Mol Cancer Ther 2005 Jan;4(1):101-12

Department of Pathology, Duke University Medical Center, P.O. Box 2900, Durham, NC 27710, USA.

View Article and Find Full Text PDF
January 2005

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Authors:
Peter Traxler Peter R Allegrini Ralf Brandt Josef Brueggen Robert Cozens Doriano Fabbro Konstantina Grosios Heidi A Lane Paul McSheehy Jürgen Mestan Thomas Meyer Careen Tang Markus Wartmann Jeanette Wood Giorgio Caravatti

Cancer Res 2004 Jul;64(14):4931-41

Oncology Research, Novartis Institutes for Biomedical Research, Klybeckstrasse, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2004

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

Authors:
Peter J Houghton Glen S Germain Franklin C Harwood John D Schuetz Clinton F Stewart Elisabeth Buchdunger Peter Traxler

Cancer Res 2004 Apr;64(7):2333-7

Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA.

View Article and Find Full Text PDF
April 2004

Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.

Authors:
Christoph Liechti Urs Séquin Guido Bold Pascal Furet Thomas Meyer Peter Traxler

Eur J Med Chem 2004 Jan;39(1):11-26

Department of Chemistry, University of Basel, St. Johanns-Ring 19, CH-4056 Basel, Switzerland.

View Article and Find Full Text PDF
January 2004

Tyrosine kinases as targets in cancer therapy - successes and failures.

Authors:
Peter Traxler

Expert Opin Ther Targets 2003 Apr;7(2):215-34

Novartis Pharma AG, Oncology Research, CH4002 Basel, Switzerland.

View Article and Find Full Text PDF
April 2003

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Authors:
Doriano Fabbro Stephan Ruetz Elisabeth Buchdunger Sandra W Cowan-Jacob Gabriele Fendrich Janis Liebetanz Jürgen Mestan Terence O'Reilly Peter Traxler Bhabatosh Chaudhuri Heinz Fretz Jürg Zimmermann Thomas Meyer Giorgio Caravatti Pascal Furet Paul W Manley

Pharmacol Ther 2002 Feb-Mar;93(2-3):79-98

Department of Oncology, Novartis Pharma Inc., WKL-125.4.10, CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF
January 2003

Integral role of the EGF receptor in HGF-mediated hepatocyte proliferation.

Authors:
Lawrence A Scheving Mary C Stevenson Jonathan M Taylormoore Peter Traxler William E Russell

Biochem Biophys Res Commun 2002 Jan;290(1):197-203

Department of Pediatrics, Medical Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article and Find Full Text PDF
January 2002